{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:17:31Z","timestamp":1787865451756,"version":"build-2784847793"},"reference-count":57,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p>Most combined oral contraceptive pills contain ethinyl estradiol (EE) with progestins. In order to minimize the pill's cardiovascular risks, the concept of using 17\u03b2-estradiol (E2), the endogenous estradiol, arose in the 1970s. Many attempts to develop a pill containing 17\u03b2-E2 have failed as cycle control was low. The first pill containing 17\u03b2-E2 was launched in 2011. This monophasic pill contains 24 pills with 1.5 mg 17\u03b2-E2 and 2.5 mg nomegestrol acetate, and four placebo pills. Studies conducted in Europe and the USA demonstrate that its Pearl index is 0.38 and 1.13, respectively. It has less influence on hemostasis, fibrinolysis markers, lipids and carbohydrate metabolism than the combined oral contraceptive levonorgestrel\/EE (150 g\/30 g and 100 \u03bcg\/20 \u03bcg). Withdrawal bleedings are shorter and lighter as compared with women using drospirenone\/EE (3 mg\/30 \u03bcg). The number of women without withdrawal bleeding is approximately 30% after 12 months. Even though its contraindications are identical to other combined oral contraceptives, this nomegestrol acetate\/E2 pill should be considered to be of interest for many women.<\/jats:p>","DOI":"10.2217\/whe.12.70","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T10:01:06Z","timestamp":1355479266000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["A New Contraceptive Pill Containing 17\u03b2-Estradiol and Nomegestrol Acetate"],"prefix":"10.1177","volume":"9","author":[{"given":"Sophie","family":"Christin-Maitre","sequence":"first","affiliation":[{"name":"Reproductive Endocrine Unit, H\u00f4pital Saint-Antoine, Universit\u00e9 Pierre et Marie Curie, 75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Laroche","sequence":"additional","affiliation":[{"name":"Reproductive Endocrine Unit, H\u00f4pital Saint-Antoine, Universit\u00e9 Pierre et Marie Curie, 75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9opoldine","family":"Bricaire","sequence":"additional","affiliation":[{"name":"Reproductive Endocrine Unit, H\u00f4pital Saint-Antoine, Universit\u00e9 Pierre et Marie Curie, 75012 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,1]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Papers of special note have been highlighted as:."},{"key":"e_1_3_1_3_2","unstructured":"of interest."},{"key":"e_1_3_1_4_2","unstructured":"of considerable interest"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.1958.11692305"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.04.004"},{"key":"e_1_3_1_7_2","unstructured":"Very good review on progestins. Illustrates the classification of progestins as well as their structure and different cardiovascular risks."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(01)00306-7"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2890"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111840"},{"key":"e_1_3_1_11_2","unstructured":"Reports the latest data on the arterial cardiovascular risk of different combined pills from the Danish cohort study. This cohort includes 1 626 158 women."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6423"},{"key":"e_1_3_1_13_2","unstructured":"Reports the latest data on the venous cardiovascular risk of different combined pills from the Danish cohort study."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgyn.2008.06.013"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(77)90447-1"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.1981.tb00038.x"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(88)90023-0"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)56210-4"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00006-1"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0940-2993(98)80034-1"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1728-4465.2010.00250.x"},{"key":"e_1_3_1_22_2","volume-title":"World Contraceptive Use","year":"2007","unstructured":"World Contraceptive Use. UN Department of Economic and Social Affairs Population Division, NY, USA (2007)."},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60478-4"},{"key":"e_1_3_1_24_2","unstructured":"Demonstrates that numbers of unwanted pregnancies and unmet contraceptive needs are still high in many developing countries. Provides evidence that use of contraception is a substantial and effective primary prevention strategy to reduce maternal mortality in developing countries."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg215"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31820095a2"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2011.02.013"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2990"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/11202820-000000000-00000"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.2217\/WHE.11.49"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.11.006"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(82)90218-6"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2011.02.002"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/11532130-000000000-00000"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.0780574"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000233184.64531.84"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1987.tb02322.x"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2003.11.009"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.554923"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der058"},{"key":"e_1_3_1_41_2","unstructured":"Illustrates the impact of a 24-day regimen using nomegestrol acetate (NOMAC)\/estradiol (E2) compared with a 21-day regimen on follicle diameters and follicle-stimulating hormone levels. Demonstrates a stronger impact of the 24-day regimen."},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2008.11.013"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.11.017"},{"issue":"5","key":"e_1_3_1_44_2","first-page":"710","article-title":"The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative","volume":"33","author":"Paris J","year":"1983","unstructured":"Paris J, Th\u00e9venot R, Bonnet P, Granero M. The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Arzneimittelforschung 33(5), 710\u2013715 (1983).","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_1_45_2","doi-asserted-by":"crossref","unstructured":"Gerrits MGF Schnabel PG Post TM Peeters PAM. Pharmacokinetic profile of nomegestrol acetate and 17\u03b2-estradiol after multiple and single dosing in healthy women. Contraception doi:10.1016\/j.contraception. 2012.07.001 (2012) (Epub ahead of print).","DOI":"10.1016\/j.contraception.2012.07.001"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.614029"},{"key":"e_1_3_1_47_2","unstructured":"Evaluates the Pearl Index and tolerance of NOMAC\/E2 in Europe Asia and Australia."},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318250c3a0"},{"key":"e_1_3_1_49_2","unstructured":"Evaluates the Pearl Index and tolerance of NOMAC\/E2 in North Central and South America."},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.604450"},{"key":"e_1_3_1_51_2","unstructured":"Evaluates the impact on hemostasis lipids and carbohydrate metabolism of NOMAC\/E2."},{"key":"e_1_3_1_52_2","volume-title":"Guideline on Clinical Investigation of Steroid Contraceptives","author":"Committee for Medicinal Products for Human Use.","year":"2005","unstructured":"Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Steroid Contraceptives. European Medicines Agency, London, UK (2005)."},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0327"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2921"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(86)90006-5"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2012.01498.x"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110855"},{"key":"e_1_3_1_58_2","first-page":"CD009038","article-title":"Quadriphasic versus monophasic oral contraceptives for contraception","volume":"11","author":"Van Vliet HA","year":"2011","unstructured":"Van Vliet HA, Raps M, Lopez LM, Helmerhorst FM. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst. Rev. 11, CD009038 (2011).","journal-title":"Cochrane Database Syst. Rev"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.12.70","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/WHE.12.70","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.12.70","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:19:36Z","timestamp":1767629976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/WHE.12.70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.2217\/WHE.12.70"],"URL":"https:\/\/doi.org\/10.2217\/whe.12.70","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"value":"1745-5057","type":"print"},{"value":"1745-5065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}